Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence. [electronic resource]
Producer: 20191024Description: 649-656 p. digitalISSN:- 1537-6591
- Adolescent
- Adult
- Age Factors
- Aged
- Aged, 80 and over
- Anti-Bacterial Agents -- therapeutic use
- Antibodies, Monoclonal -- therapeutic use
- Antibodies, Neutralizing -- therapeutic use
- Broadly Neutralizing Antibodies
- Clostridioides difficile -- drug effects
- Clostridium Infections -- mortality
- Fecal Microbiota Transplantation
- Female
- Fidaxomicin -- administration & dosage
- Humans
- Male
- Metronidazole -- administration & dosage
- Middle Aged
- Patient Readmission
- Recurrence
- Risk Factors
- Secondary Prevention
- Vancomycin -- administration & dosage
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.